Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.98 |
| ▸ | TYMP | P19971 | 3/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cidofovir Anhydrous SCHEMBL1389452 | 1.00 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL14682730 | 1.00 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL151807 | 1.00 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL2946566 | 0.99 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL20770422 | 0.99 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL12988503 | 0.99 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL934593 | 0.99 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL2946561 | 0.99 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL28935227 | 0.99 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL27629017 | 0.99 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31167 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | claimed |
| EP-4748448-A2 | USE OF MARIBAVIR FOR THE TREATMENT OF AND TREATMENT REGIMENS THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-05-27 | — | — | EP | claimed |
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12631653-B2 | Methods for diagnosing and treating uveitis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-19 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12611440-B2 | Fusion proteins and uses thereof | SYNKLINO A/S (DK) | 2026-04-28 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-5677308-A | Method for alleviating spasmodic torticollis | LERNER A MARTIN (US) | 1997-10-14 | — | — | US | claimed |
| WO-1997026275-A1 | PROTEIN OCCLUSION FOR DELIVERY OF SMALL MOLECULES | PANAYOTATOS NIKOS (US) | 1997-07-24 | — | — | WO | claimed |
| WO-1997013528-A1 | A PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF AN ACTIVE SUBSTANCE TO OR THROUGH A SKIN OR MUCOSAL SURFACE | GS DEVELOPMENT AB (SE) | 1997-04-17 | — | — | WO | claimed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1996024355-A1 | NOVEL PHARMACEUTICAL COMBINATION | ASTRA AKTIEBOLAG (SE) | 1996-08-15 | — | — | WO | claimed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | claimed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | claimed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | claimed |
| EP-0559744-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1993-09-15 | — | — | EP | claimed |
| WO-1992009287-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-06-11 | — | — | WO | claimed |